Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

Maura N. Dickler; Cristina Saura; Donald A. Richards; Ian E. Krop; Andrés Cervantes; Philippe L. Bedard; Manish R. Patel; Lajos Pusztai; Mafalda Oliveira; Alison K. Cardenas; Na Cui; Timothy R. Wilson; Thomas J. Stout; Michael C. Wei; Jerry Y. Hsu; José Baselga

doi:10.1158/1078-0432.ccr-18-0613

Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-18-0613 ◽

2018 ◽

Vol 24 (18) ◽

pp. 4380-4387 ◽

Cited By ~ 26

Author(s):

Maura N. Dickler ◽

Cristina Saura ◽

Donald A. Richards ◽

Ian E. Krop ◽

Andrés Cervantes ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Study ◽

Advanced Breast ◽

Hormone Receptor Positive

Download Full-text

Phase II Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer

Case Medical Research ◽

10.31525/ct1-nct03939871 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Study ◽

Advanced Breast ◽

Oral Vinorelbine ◽

Hormone Receptor Positive

Download Full-text

Abstract P6-12-01: Phase II study of taselisib (GDC-0032) plus fulvestrant in HER2-negative, hormone receptor-positive advanced breast cancer: Analysis byPIK3CAandESR1mutation status from circulating tumor DNA

10.1158/1538-7445.sabcs16-p6-12-01 ◽

2017 ◽

Cited By ~ 2

Author(s):

MN Dickler ◽

C Saura ◽

M Oliveira ◽

DA Richards ◽

IE Krop ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Study ◽

Circulating Tumor Dna ◽

Advanced Breast ◽

Hormone Receptor Positive ◽

Tumor Dna

Download Full-text

Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER)

European Journal of Cancer ◽

10.1016/j.ejca.2021.11.010 ◽

2022 ◽

Vol 161 ◽

pp. 26-37

Author(s):

J. Albanell ◽

M.T. Martínez ◽

M. Ramos ◽

M. O'Connor ◽

L. de la Cruz-Merino ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Study ◽

Advanced Breast ◽

Hormone Receptor Positive ◽

Randomized Phase Ii

Download Full-text

Prevention of stomatitis in patients with hormone receptor–positive advanced breast cancer treated with everolimus plus exemestane: A phase II study of a steroid-based mouthwash.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps661 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS661-TPS661 ◽

Cited By ~ 1

Author(s):

Hope S. Rugo ◽

Mark Steven Chambers ◽

Jennifer Keating Litton ◽

Ingrid A. Mayer ◽

Jaqueline Willemann Rogerio ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Study ◽

Advanced Breast ◽

Hormone Receptor Positive

Download Full-text

A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.520 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 520-520 ◽

Cited By ~ 18

Author(s):

Maura N. Dickler ◽

Cristina Saura ◽

Donald A. Richards ◽

Ian E. Krop ◽

Andres Cervantes ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Study ◽

Advanced Breast ◽

Pi3k Inhibitor ◽

Hormone Receptor Positive

Download Full-text

PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer

Contemporary Clinical Trials Communications ◽

10.1016/j.conctc.2018.05.012 ◽

2018 ◽

Vol 10 ◽

pp. 190-192

Author(s):

Filipa Lynce ◽

Mervat Saleh ◽

Ayesha Shajahan-Haq ◽

Christopher Gallagher ◽

Asma Dilawari ◽

...

Keyword(s):

Breast Cancer ◽

African American ◽

Advanced Breast Cancer ◽

African American Women ◽

Phase Ii ◽

Hormone Receptor ◽

Advanced Breast ◽

Safety Study ◽

American Women ◽

Hormone Receptor Positive

Download Full-text

Abstract OT3-02-04: Randomised phase II study evaluating, as first-line chemotherapy, single-agent oral vinorelbine administered with two different schedules in patients with hormone receptor positive, HER2-negative advanced breast cancer (TempoBreast-1 trial)

10.1158/1538-7445.sabcs15-ot3-02-04 ◽

2016 ◽

Cited By ~ 1

Author(s):

J De la Haba ◽

M Cazzaniga ◽

G Freyer ◽

L Costa ◽

E Petru ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Study ◽

Single Agent ◽

First Line ◽

Oral Vinorelbine ◽

Hormone Receptor Positive ◽

Line Chemotherapy

Download Full-text

Abstract OT2-01-09: PALINA: A phase II safety study of palbociclib in combination with letrozole in African American women with hormone receptor positive HER2 negative advanced breast cancer

10.1158/1538-7445.sabcs16-ot2-01-09 ◽

2017 ◽

Author(s):

F Lynce ◽

A Shajahan-Haq ◽

L Cai ◽

D Graham ◽

C Gallagher ◽

...

Keyword(s):

Breast Cancer ◽

African American ◽

Advanced Breast Cancer ◽

African American Women ◽

Phase Ii ◽

Hormone Receptor ◽

Advanced Breast ◽

Safety Study ◽

American Women ◽

Hormone Receptor Positive

Download Full-text

A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2019.06.005 ◽

2020 ◽

Vol 20 (2) ◽

pp. 89-97 ◽

Cited By ~ 2

Author(s):

Denise A. Yardley ◽

William Liggett ◽

Mark Mainwaring ◽

Aurelio Castrellon ◽

Laura Blakely ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Endocrine Therapy ◽

Phase Ii ◽

Hormone Receptor ◽

Advanced Breast ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Hormone Receptor Positive

Download Full-text

5072 Independent central review of clinical benefit rates in FIRST: a Phase II comparison of fulvestrant 500 mg with anastrozole 1 mg as first-line endocrine therapy for postmenopausal women with hormone receptor positive advanced breast cancer

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)70964-4 ◽

2009 ◽

Vol 7 (2) ◽

pp. 282 ◽

Cited By ~ 1

Author(s):

J.P.O. Lindemann ◽

J.F.R. Robertson ◽

M.J. Ellis ◽

Y. Menu ◽

E.J. Macpherson ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Endocrine Therapy ◽

Phase Ii ◽

Clinical Benefit ◽

Hormone Receptor ◽

Advanced Breast ◽

First Line ◽

Hormone Receptor Positive

Download Full-text